Lung precision oncology program (lpop) | veterans affairs

CLINICAL TRIAL TITLE: TROPION-LUNG10: A Phase III, Randomised, Open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig (AZD2936) or Rilvegostomig

Monotherapy Versus Pembrolizumab Monotherapy for the First-line Treatment of Participants With Locally-advanced or Metastatic Non-squamous NSCLC With High PD-L1 Expression (TC ? 50%) and

Without Actionable Genomic Alterations  (Astra Zeneca) CLINICAL TRIAL OVERVIEW: The purpose of this research is to test investigational drugs called rilvegostomig and datopotamab deruxtecan

(Dato-DXd), alone or in combination, to determine if they are well tolerated in treating locally advanced or metastatic non-squamous non-small cell lung cancer. The experimental treatments

are compared with an approved treatment called pembrolizumab.  CLINICAL TRIAL NUMBER: NCT06357533 For more information, please contact: DR. HUANG, PI | [email protected]  |  EBONY NELSON,

PROGRAM MANAGER | [email protected] | ex 220727 ------------------------- CLINICAL TRIAL TITLE: TROPION-LUNG12: A Phase III, Randomised, Open-label, Global Study of Adjuvant Datopotamab

Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma

Non-small Cell Lung Cancer who are ctDNA-positive or Have High-risk Pathological Features (Astra Zeneca) CLINICAL TRIAL OVERVIEW: The purpose of this research is to learn if an

investigational drug called rilvegostomig, when used alone or in combination with another anti-cancer drug called datopotamab deruxtecan (also called Dato-DXd), given intravenously after

surgery, will work and be safe for the treatment of Stage I NSCLC.  CLINICAL TRIAL NUMBER: NCT06564844 For more information, please contact: DR. HUANG, PI | [email protected]  |  EBONY

NELSON, PROGRAM MANAGER | [email protected] | ex 220727 ------------------------- CLINICAL TRIAL TITLE: (PEMBRO EZ) Phase Ib/II study of safety and efficacy of EZH2 inhibitor, 

tulmimetostat, and PD-1 blockade for treatment of advanced non-small cell lung cancer (VA ORD) CLINICAL TRIAL OVERVIEW:  CLINICAL TRIAL NUMBER: NCT05467748 For more information, please

contact: DR. SHIN, PI | [email protected]| EBONY NELSON, PROGRAM MANAGER | [email protected] | ex 220727 ------------------------- CLINICAL TRIAL TITLE: RIVAL Repositioning Immunotherapy

in Veterans with Lung Cancer (VA ORD) CLINICAL TRIAL OVERVIEW: The purpose of this research is to gather information on the safety and effectiveness of giving chemotherapy + immunotherapy

followed by radiation and then immunotherapy. And whether this approach is more beneficial than current standard treatment of chemotherapy and radiation given concurrently, followed by

immunotherapy. While all of these medications are FDA approved for your type of cancer, the research component of this study is giving immunotherapy with chemotherapy at the start of

treatment. CLINICAL TRIAL NUMBER: NCT06275360 For more information, please contact: DR. SHIN, PI | [email protected]| EBONY NELSON, PROGRAM MANAGER | [email protected] | ex 220727